TEVA(US:TEVA)2026-01-28 12:20Financial Projections - Teva expects 2025 revenues to be in the range of $16.8 billion to $17.0 billion, with a lower point of the range contributing an additional $500 million from expected duvakitug milestones[3] - The operating margin for 2025 is projected to be approximately 26.2% to 27.1%, with a mid to high point of the range contributing around 80%-85%[3] - Adjusted EBITDA for 2025 is anticipated to be between $4.8 billion and $5.0 billion, with a midpoint contribution of approximately $400 million to $430 million from milestones[3] - Free cash flow is expected to be between $1.6 billion and $1.9 billion, with a higher point of the range contributing around $500 million[3] - Teva's revenues for 2026 are projected to be flat to slightly down compared to 2025, with low-single digit growth expected by 2027 and mid-single digit CAGR by 2030[5] - Operating profit is expected to grow by 30% in 2027, exceeding 30% growth thereafter[5] Cost Savings and Transformation - Cumulative transformation programs are projected to generate savings of approximately $450 million to $500 million by 2026 and around $700 million by 2027[5] - Teva's transformation strategy focuses on becoming a leading innovative biopharmaceutical company, leveraging its generics business and late-stage innovative pipeline[6] Growth Drivers - Teva's innovative brands, including AUSTEDO, AJOVY, and UZEDY, are driving growth and reshaping the financial outlook[6] Capital Allocation - The company is committed to disciplined capital allocation and aims to secure an investment-grade credit rating[6]